Cellebrite DI (NASDAQ:CLBT - Get Free Report) had its price target dropped by JPMorgan Chase & Co. from $20.00 to $16.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price objective would indicate a potential upside of 45.79% from the stock's current price.
Several other brokerages have also issued reports on CLBT. DA Davidson decreased their price target on shares of Cellebrite DI from $22.00 to $15.00 and set a "buy" rating for the company in a research note on Friday. Weiss Ratings upgraded shares of Cellebrite DI from a "sell (d+)" rating to a "hold (c-)" rating in a report on Monday, May 18th. Finally, Needham & Company LLC lowered their price objective on Cellebrite DI from $15.00 to $12.50 and set a "buy" rating for the company in a research note on Friday. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Cellebrite DI currently has an average rating of "Moderate Buy" and an average price target of $18.30.
Check Out Our Latest Research Report on Cellebrite DI
Cellebrite DI Price Performance
CLBT traded up $0.17 on Friday, hitting $10.97. The company had a trading volume of 4,049,603 shares, compared to its average volume of 2,117,300. Cellebrite DI has a 52-week low of $9.58 and a 52-week high of $19.98. The stock has a fifty day simple moving average of $14.52 and a 200-day simple moving average of $14.05. The firm has a market capitalization of $2.74 billion, a P/E ratio of 39.19, a P/E/G ratio of 1.89 and a beta of 1.18.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.05 by $0.06. The company had revenue of $131.14 million during the quarter, compared to analysts' expectations of $131.87 million. Cellebrite DI had a return on equity of 18.38% and a net margin of 14.48%. Equities research analysts expect that Cellebrite DI will post 0.41 earnings per share for the current fiscal year.
Insider Transactions at Cellebrite DI
In other news, CEO Thomas E. Hogan sold 139,713 shares of the company's stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $15.39, for a total transaction of $2,150,183.07. Following the transaction, the chief executive officer directly owned 790,548 shares of the company's stock, valued at $12,166,533.72. This represents a 15.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the sale, the executive owned 440,101 shares of the company's stock, valued at $5,620,089.77. The trade was a 2.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 297,934 shares of company stock worth $4,631,972 over the last quarter. 5.70% of the stock is currently owned by insiders.
Institutional Trading of Cellebrite DI
Hedge funds have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Cellebrite DI by 16.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company's stock worth $3,362,000 after purchasing an additional 24,881 shares in the last quarter. Geode Capital Management LLC increased its holdings in Cellebrite DI by 16.2% in the 2nd quarter. Geode Capital Management LLC now owns 314,440 shares of the company's stock valued at $5,029,000 after acquiring an additional 43,898 shares during the last quarter. Invesco Ltd. lifted its stake in Cellebrite DI by 6.4% in the 2nd quarter. Invesco Ltd. now owns 3,505,552 shares of the company's stock worth $56,089,000 after purchasing an additional 209,473 shares in the last quarter. First Trust Advisors LP bought a new stake in shares of Cellebrite DI in the second quarter worth about $341,000. Finally, Marshall Wace LLP purchased a new stake in shares of Cellebrite DI in the second quarter worth about $4,472,000. Institutional investors own 45.88% of the company's stock.
More Cellebrite DI News
Here are the key news stories impacting Cellebrite DI this week:
- Positive Sentiment: Cellebrite reported adjusted second-quarter EPS of $0.11, ahead of the $0.05 consensus cited by MarketBeat. Subscription revenue continued to grow, and management raised its adjusted EBITDA target. Cellebrite earnings and outlook announcement
- Positive Sentiment: DA Davidson and Needham retained Buy ratings, with their revised price targets of $15 and $12.50 respectively still implying potential upside from recent levels. Analyst price target updates
- Neutral Sentiment: Nearly 20,000 CLBT call options traded, far above typical volume. The activity may indicate some traders expect a rebound, but options positioning is speculative and does not change the company’s fundamentals.
- Neutral Sentiment: Cellebrite named Shiven Ramji as CEO, succeeding Thomas E. Hogan in a planned transition. The change could support a strategic reset, but leadership turnover adds uncertainty during a period of weaker growth. CEO transition announcement
- Negative Sentiment: Revenue of $131.14 million slightly missed estimates, while analysts highlighted an annual recurring revenue shortfall. More importantly, third-quarter revenue guidance of $145 million-$148 million and full-year guidance of $555 million-$561 million were below consensus expectations of $150.3 million and $568.1 million. The company also lowered its full-year ARR outlook. Cellebrite guidance report
- Negative Sentiment: Several law firms announced investigations into possible securities-law violations and whether Cellebrite’s earlier projections and disclosures were accurate. These are allegations, not established findings, but they increase legal and reputational risk. Cellebrite investigation notice
- Negative Sentiment: CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his holdings by about 15%. While the sale may reflect personal planning or the CEO transition, its timing is a negative sentiment factor. SEC insider sale filing
About Cellebrite DI
(
Get Free Report)
Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.
The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
